Halozyme Therapeutics (HALO) Competitors $61.19 +1.16 (+1.93%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$61.18 0.00 (-0.01%) As of 05/2/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock HALO vs. BIIB, UTHR, BMRN, INCY, EXEL, NBIX, EXAS, RGEN, MDGL, and IONSShould you be buying Halozyme Therapeutics stock or one of its competitors? The main competitors of Halozyme Therapeutics include Biogen (BIIB), United Therapeutics (UTHR), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Exact Sciences (EXAS), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry. Halozyme Therapeutics vs. Biogen United Therapeutics BioMarin Pharmaceutical Incyte Exelixis Neurocrine Biosciences Exact Sciences Repligen Madrigal Pharmaceuticals Ionis Pharmaceuticals Halozyme Therapeutics (NASDAQ:HALO) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, community ranking, analyst recommendations, valuation, profitability, earnings, dividends and risk. Do institutionals & insiders hold more shares of HALO or BIIB? 97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 2.4% of Halozyme Therapeutics shares are owned by company insiders. Comparatively, 0.2% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has better valuation & earnings, HALO or BIIB? Biogen has higher revenue and earnings than Halozyme Therapeutics. Biogen is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHalozyme Therapeutics$1.02B7.49$281.59M$3.4317.94Biogen$9.68B1.87$1.63B$11.1911.04 Which has more risk & volatility, HALO or BIIB? Halozyme Therapeutics has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.13, indicating that its share price is 87% less volatile than the S&P 500. Is HALO or BIIB more profitable? Halozyme Therapeutics has a net margin of 43.74% compared to Biogen's net margin of 16.87%. Halozyme Therapeutics' return on equity of 157.78% beat Biogen's return on equity.Company Net Margins Return on Equity Return on Assets Halozyme Therapeutics43.74% 157.78% 25.34% Biogen 16.87%14.98%8.76% Do analysts rate HALO or BIIB? Halozyme Therapeutics currently has a consensus price target of $62.89, suggesting a potential upside of 2.22%. Biogen has a consensus price target of $196.59, suggesting a potential upside of 59.12%. Given Biogen's higher possible upside, analysts clearly believe Biogen is more favorable than Halozyme Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Halozyme Therapeutics 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60Biogen 0 Sell rating(s) 20 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.38 Does the MarketBeat Community prefer HALO or BIIB? Biogen received 1294 more outperform votes than Halozyme Therapeutics when rated by MarketBeat users. Likewise, 71.32% of users gave Biogen an outperform vote while only 69.51% of users gave Halozyme Therapeutics an outperform vote. CompanyUnderperformOutperformHalozyme TherapeuticsOutperform Votes52969.51% Underperform Votes23230.49% BiogenOutperform Votes182371.32% Underperform Votes73328.68% Does the media refer more to HALO or BIIB? In the previous week, Biogen had 25 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 56 mentions for Biogen and 31 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.76 beat Biogen's score of 0.44 indicating that Halozyme Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 15 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 16 Very Positive mention(s) 3 Positive mention(s) 13 Neutral mention(s) 8 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryHalozyme Therapeutics beats Biogen on 10 of the 18 factors compared between the two stocks. Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HALO vs. The Competition Export to ExcelMetricHalozyme TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.60B$2.97B$5.55B$8.05BDividend YieldN/A1.87%5.09%4.22%P/E Ratio17.9430.5322.7318.81Price / Sales7.49500.45406.97107.57Price / Cash12.35168.6838.1834.62Price / Book20.863.226.814.34Net Income$281.59M-$72.35M$3.22B$247.85M7 Day Performance1.71%4.14%2.40%2.83%1 Month Performance-2.37%7.74%3.77%3.46%1 Year Performance54.51%-22.32%16.96%5.87% Halozyme Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HALOHalozyme Therapeutics4.0299 of 5 stars$61.19+1.9%$62.89+2.8%+53.7%$7.56B$1.02B17.84390Upcoming EarningsAnalyst RevisionBIIBBiogen4.7168 of 5 stars$119.12+0.2%$203.07+70.5%-42.1%$17.44B$9.68B10.658,720Earnings ReportAnalyst ForecastNews CoverageUTHRUnited Therapeutics4.9879 of 5 stars$297.04+1.9%$390.17+31.4%+14.1%$13.34B$2.88B13.05980Earnings ReportAnalyst ForecastInsider TradePositive NewsBMRNBioMarin Pharmaceutical4.9303 of 5 stars$62.98-0.5%$93.14+47.9%-26.0%$12.02B$2.85B28.633,080Analyst ForecastNews CoveragePositive NewsGap UpINCYIncyte4.7431 of 5 stars$59.52+0.6%$74.69+25.5%+17.8%$11.52B$4.24B220.452,320Earnings ReportAnalyst ForecastAnalyst RevisionEXELExelixis4.0044 of 5 stars$38.44+2.7%$37.59-2.2%+79.0%$10.59B$2.17B21.721,220Short Interest ↑Analyst RevisionPositive NewsNBIXNeurocrine Biosciences4.8847 of 5 stars$106.46-0.3%$160.90+51.1%-21.6%$10.53B$2.36B32.361,200Upcoming EarningsEXASExact Sciences4.5218 of 5 stars$45.59+0.3%$69.25+51.9%-14.8%$8.47B$2.76B-8.186,400Earnings ReportAnalyst ForecastNews CoveragePositive NewsGap UpRGENRepligen4.6477 of 5 stars$143.63-0.8%$176.82+23.1%-14.9%$8.06B$634.44M-281.632,020Earnings ReportAnalyst UpgradeAnalyst RevisionNews CoverageGap UpMDGLMadrigal Pharmaceuticals4.6214 of 5 stars$331.29+1.4%$409.00+23.5%+46.0%$7.31B$180.13M-13.2190Earnings ReportAnalyst ForecastNews CoveragePositive NewsIONSIonis Pharmaceuticals4.403 of 5 stars$29.74+0.1%$56.72+90.7%-23.9%$4.73B$705.14M-9.78800Earnings ReportAnalyst ForecastInsider TradeNews CoveragePositive News Related Companies and Tools Related Companies BIIB Competitors UTHR Competitors BMRN Competitors INCY Competitors EXEL Competitors NBIX Competitors EXAS Competitors RGEN Competitors MDGL Competitors IONS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HALO) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredMassive red flag about American consumerWhy is the U.S. Dollar suddenly crashing? Pundits on either side of the aisle have been warning that the U....Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Halozyme Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy HALO Stock Free HALO Stock Alerts